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Background: Assessment of therapeutic activity of drugs blocking immune checkpoints such as CTLA-4 and
PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear anew before regressing, due to intratumoral
inflammation. We assessed whether circulating tumor DNA (ctDNA) levels could serve as an early indicator of true
changes in tumor burden in patients undergoing treatment with these agents.
Findings: Tumors from 12 patients with metastatic melanoma undergoing treatment with checkpoint blocking drugs
were analyzed for the presence of hotspot somatic mutations in BRAF, cKIT, NRAS, and TERT. Plasma was collected
serially from each patient and levels of ctDNA were compared with radiologic and clinical outcomes.
In 5 of 10 patients studied, mutations were detected in BRAF(1), NRAS(2), TERT(1) and ALK(1). Analysis of plasma from 4
of 5 patients identified mutations identical to those found in tumor specimens. Plasma ctDNA levels ranged from
undetectable (<0.01%) to 5.5% of total circulating cell-free DNA. In 3 patients, increasing ctDNA levels correlated with
progressive disease assessed by radiography. In one patient, ctDNA levels increased after undergoing a needle biopsy
of a tumor deposit. In another patient, ctDNA levels increased initially as lymphadenopathy progressed by examination,
but then became undetectable 3 weeks prior to clinical improvement.
Conclusions: Levels of ctDNA correlated with clinical and radiologic outcomes, and, in one case, preceded eventual
tumor regression. Further prospective analysis is required to assess the utility of ctDNA as an early biomarker of clinical
outcomes in patients receiving immune checkpoint blocking drugs.
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Background
Our group and others have previously reported that circu-
lating tumor DNA (ctDNA) can be detected in the plasma
of patients with advanced melanoma and other malignan-
cies [1-6]. Furthermore, levels of ctDNA can correlate
with changes in tumor burden in response to surgery or
chemotherapy [7,8]. The current study tested the hypoth-
esis that ctDNA levels in the plasma of patients with* Correspondence: evanlipson@jhmi.edu
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Dedication waiver (http://creativecommons.or
unless otherwise stated.metastatic melanoma could serve as early biomarkers of
therapeutic responses to immune checkpoint blockade
therapy.
Monoclonal antibodies blocking immune checkpoint
molecules such as Programmed Death-1 (PD-1; nivolu-
mab and pembrolizumab), PD-ligand 1 (PD-L1; BMS-
936559, MPDL3280A, and MEDI4736), and Cytotoxic T
lymphocyte-associated Antigen 4 (CTLA-4; ipilimumab),
have mechanisms of action which differ significantly from
standard cytotoxic therapies [9]. This creates challenges
for assessing therapeutic activity. Checkpoint blockingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the tumor, and the kinetics of tumor regression may be
delayed [10,11]. In some cases, tumors assessed using con-
ventional CT imaging criteria (RECIST; [12] appear to en-
large during therapy before regressing. In other patients,
new tumors appear on therapy which later regress. Some
tumors remain stable in size for a prolonged period of
time, even after treatment has been stopped [13-16]. It
has been proposed that apparent tumor progression may,
in some cases, reflect intratumoral inflammation rather
than actual tumor growth [17]. Non-invasive indicators of
changes in tumor burden could provide early information
about therapeutic outcomes and avoid unnecessary expos-
ure to potentially serious immune-related toxicities in pa-
tients with true disease progression [18].
Methods
Twelve patients with metastatic melanoma who were
scheduled to receive treatment with an immune check-
point blocking drug at our institution, including ipili-
mumab (anti-CTLA-4) or BMS-936559 (anti-PD-L1)
(NCT00729664, Ref. [14]), provided informed consent
to participate in this IRB-approved study. Archived
formalin-fixed, paraffin-embedded tumor specimens were
analyzed for common, recurrent somatic sequence muta-
tions in BRAF, cKIT, NRAS and TERT [19] using standard-
ized pyrosequencing, melting curve analysis, or Sanger
sequencing techniques, as previously described [20,21].
Methodological details for the 5 patients in whom a tumor
mutation was detected are included in Additional file 1:
Table S1. In one case, whole exome sequencing wasTable 1 Tumor-specific mutation analysis of 10 melanoma tum
IDa BRAF cKIT NRAS Other
01 WT WT WT Chr5: 1,295,228-9
GG > AA (TERT)b
03 1799T > A WT NT NT
05 WT WT WT NT
06 WT WT WT NT
07 WT WT WT NT
08 WT WT 182A > G NT
09 WT WT WT NT
10 WT WT 181C > A NT
11 WT WT WT Chr2: 29,551,215
C > T (ALK)b
12 WT WT NTc NT
Archived formalin-fixed, paraffin-embedded tumor specimens were analyzed for co
[19] using standardized pyrosequencing, melting curve analysis, or Sanger sequenc
(5853):1108-13. and Parsons et. al., Science. 2008 Sep 26;321(5897):1807-12.). No mutat
with melanoma (BRAF, NRAS, TERT) were found in 4 patients. For one subject (#11) who
sequencing analysis of tumor and normal samples was employed to identify tumor-sp
tested; PR, partial response; PD, progressive disease; CR, complete response; apatient ID
prior to completing their courses of therapy are not included in Table 1; bgenomic posperformed to identify a unique tumor-specific mutation
that could be used to quantify ctDNA in plasma. Sample
library construction, exome capture, next generation se-
quencing, and bioinformatic analyses were performed at
Personal Genome Diagnostics (Baltimore, MD). Genomic
DNA, obtained from circulating leukocytes, was fragmen-
ted and used for Illumina TruSeq library construction
(Illumina, San Diego, CA). Exonic regions were captured
in solution using the Agilent SureSelect 50 Mb kit (version
4) according to the manufacturer’s instructions (Agilent,
Santa Clara, CA). Paired-end sequencing, resulting in 100
bases from each end of the fragments, was performed
using a HiSeq 2000 Genome Analyzer System (Illumina,
San Diego, CA). The sequences were aligned to the hu-
man genome reference sequence (hg18) using the Eland
algorithm of CASAVA 1.7 software (Illumina, San Diego,
CA). The chastity filter of the BaseCall software of
Illumina was used to select sequence reads for subse-
quent analysis. The ELANDv2 algorithm of CASAVA 1.7
software (Illumina, San Diego, CA) was then applied to
identify point mutations and small insertions and dele-
tions. Potential somatic mutations were filtered and visu-
ally inspected as described previously [22,23].
Blood was collected in K2EDTA collection vials from
each patient prior to therapy, and then at approximately 2-
4 week intervals during treatment. Within 3 hours of col-
lection, samples were centrifuged at 810 g for ten minutes
at room temperature. In a sterile biosafety cabinet, plasma
was pooled and aliquoted. Samples were centrifuged at
18,000 g for ten minutes at room temperature. The super-
natant was transferred to cryovials and immediately storedor specimens
Therapy Radiographic response ctDNA level
analyzed?










mmon, recurrent somatic sequence mutations in BRAF, cKIT, NRAS and TERT
ing techniques, as previously described (Wood et. al., Science. 2007 Nov 16;318
ion was detected in 5 of 10 patients. Previously reported mutations associated
se tumor was found to be wild type for each of the above genes, whole exome
ecific (somatic) sequence and copy number alterations. (WT, wild type; NT, not
numbers are not sequential as 2 patients who died due to disease progression
ition, hg19; cNo PCR amplified product was obtained after repeated attempts).
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and immediately stored at -80C. DNA was extracted
using the QIAamp Circulating Nucleic Acid Kit (Qiagen,
Valencia, CA). BEAMing technology (Beads, Emulsifica-
tion, Amplification and Magnetics; Inostics, Hamburg,
Germany) was used to detect and quantify circulating























































Figure 1 Correlation of ctDNA measurements with clinical course. A)
disease assessed by radiography in patient #08, a 52-year-old man with metast
(BRAF V600E) in patient #03, a 69-year-old woman with metastatic melanoma
a lower extremity soft tissue metastasis on treatment day 155 (red arrow). SLDPCR and next-generation sequencing approach was re-
quired due to difficulty in generating a BEAMing probe
specific to the TERT promoter locus, due to high GC con-
tent. Briefly, DNA was partitioned into reactions each
containing approximately 1,000 genomic equivalents (GE),
from which a mutation was called if present in at least
two independent PCR and next-generation sequencingR2=0.3188
Increasing levels of ctDNA (NRAS A182G) correlate with progressive
atic melanoma who received BMS-936559 (anti-PD-L1). B) Levels of ctDNA
who received BMS-936559, increased substantially after a needle biopsy of
, sum of longest tumor diameters.
Ipilimumab dose #3: Hoarseness persists. 
Exam: 6 stable or decreasing  (0.5 -1 cm  
diameter) left cervical and supraclavicular 













Ipilimumab dose #1: 6 palpable (0.5 - 1.5  
cm diameter) left cervical and  
supraclavicular lymph nodes. 
Ipilimumab dose #2: Patient developed  
hoarseness. 6 enlarged (1-2 cm diameter)  
left cervical and supraclavicular lymph 
nodes.
Ipilimumab dose #4 held for elevated liver  
transaminases. Hoarseness improved;   
neck lymphadenopathy decreased 
considerably in size, barely palpable.   
No palpable 
adenopathy
PET/CT scan: near complete  
resolution of metastatic disease in  












Figure 2 (See legend on next page.)
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Figure 2 Clinical course and ctDNA measurements for patient #01, a 68-year-old woman with biopsy-proven unresectable melanoma
of the left neck and left supraclavicular regions. She received ipilimumab as first-line therapy, to which she had an “immune-related” response.
A) Treatment timeline. Ipilimumab (anti-CTLA-4, 3 mg/kg) was administered intravenously every 3 weeks for 3 doses. ctDNA levels (TERTmut) increased
initially as metastatic lymph nodes enlarged on physical examination (week 3), but ctDNA became undetectable at week 6 even though metastatic
lymph nodes were still palpable. Significant disease regression was noted clinically 3 weeks later and complete disease resolution was demonstrated
on CT and FDG-PET scans performed 4 months after treatment initiation. B) CT and FDG-PET images demonstrating the resolution of palpable cervical
lymphadenopathy after administration of ipilimumab.
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were quantified by taking the total mutant observations
divided by the total GE analyzed. The lower limit of sensi-
tivity for this assay was dependent on the total GE ana-
lyzed, and ranged from 1,603 to 15,308, yielding a
sensitivity of >0.1%. Results were correlated with radio-
logic and clinical outcomes.
Results
Two patients died due to disease progression prior to
completing their courses of therapy. Of ten evaluable pa-
tients, one demonstrated a mutation in BRAF (1799T >A
(V600E)), none in cKIT and two in NRAS (182A >G
(Q61R), 181C > A (Q61K)). TERT mutation testing was
performed on 2 patients whose tumors were wild-type for
the 3 genes listed above, and one demonstrated a muta-
tion (Chr5: 1,295,228-9;GG >AA). In another patient,
whole exome sequencing analysis of tumor and normal
samples revealed a mutation in ALK (Chr2: 29,551,215;
C > T); plasma DNA levels were not analyzed for this pa-
tient (Table 1).
Analysis of plasma from 4 patients identified muta-
tions identical to those found in tumor specimens
(BRAF, NRAS, TERT). Plasma ctDNA levels measured as a
fraction of total GE in cell-free DNA ranged from below
the detection limits of the PCR/next-generation sequen-
cing assay (<0.1%) or the BEAMing assay (<0.01%) to 5.5%
of total circulating DNA.
Increasing levels of tumor-derived ctDNA were seen in
conjunction with progressive disease assessed by radiog-
raphy in three patients. In one patient, ctDNA levels in-
creased substantially after a needle biopsy of a tumor
deposit was performed, validating the sensitivity of these
methods (Figure 1).
In one patient who experienced an “immune-related” re-
sponse to ipilimumab therapy – clinical disease progres-
sion early in the treatment course, followed by a sustained
response to treatment – plasma levels of tumor-derived
DNA became undetectable several weeks prior to clinical
tumor regression (Figure 2).
Discussion
Clinical management of patients undergoing therapy with
immune checkpoint blocking drugs can be challenging.
Radiographic changes seen on conventional CT scans canbe misleading, as tumors may appear to enlarge or appear
anew before later regressing. Furthermore, prolonged dis-
ease stabilization may contribute to overall survival bene-
fits. Although serum levels of CEA, CA19-9 and PSA can
be used as surrogate markers of tumor burden changes in
colon, pancreas and prostate cancer, many cancers such
as melanoma have no validated tumor marker. However,
genetic alterations contained in human cancers, including
gene deletions or amplifications, point mutations and
chromosomal rearrangements, can distinguish cell-free
tumor DNA from normal DNA and can serve as personal-
ized biomarkers of disease in patients with advanced mel-
anoma and other malignancies.
Approximately 90% of melanomas harbor a point mu-
tation in BRAF, NRAS or cKIT [26]. Likewise, mutations
in the TERT promoter have been reported in approxi-
mately 40-70% of melanoma tumors [19,27]. These high-
frequency mutations could be used to track ctDNA levels
in a majority of patients with metastatic melanoma. For
patients with other tumor types with more diverse and/or
private mutations, whole exome sequencing may be re-
quired in order to identify a genetic alteration suitable for
detection in the circulation.
In this pilot study, changes in ctDNA levels correlated
with physical examination and radiologic outcomes in
patients receiving checkpoint blockade agents. In one
case, decreasing ctDNA levels preceded eventual clinical
and radiographic tumor regression. Thus, ctDNA levels
may serve as an early biomarker, reflecting tumor burden
changes more quickly than those detected using CT radi-
ography. Although these findings require further prospect-
ive analysis and validation in larger numbers of patients,
an easily-measured, accurate, plasma-based marker of dis-
ease such as ctDNA would potentially change patient
management in several settings. First, decreasing levels of
ctDNA detected during the appearance of clinical or
radiographic disease progression might aid in the early
identification of patients whose tumors will soon respond
to treatment and, therefore, should continue on therapy.
Second, ctDNA levels that are rising in the period between
radiologic evaluations might prompt the clinician to con-
sider early radiologic restaging, since rising ctDNA could
indicate true disease progression, or tumor lysis preceding
regression. Third, in patients whose cancers recur after a
prolonged period of regression off therapy [13], ctDNA
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prompt a re-initiation of therapy. Lastly, in early-stage pa-
tients who have undergone surgical resection of disease,
plasma evidence of residual disease may influence recom-
mendations for adjuvant therapy [28,29].
The initial increase in levels of ctDNA in patient #01
potentially supports the theory that apparent tumor pro-
gression may, in some cases, reflect intratumoral inflam-
mation and immune-mediated tumor destruction, rather
than actual tumor growth [17]. In analogous fashion, an
acute, destructive event within a tumor deposit in patient
#03 (i.e., a physical disruption with a biopsy needle) ap-
peared to significantly increase ctDNA levels. One ques-
tion that stems from this observation concerns the
possible seeding of distant disease by disruption of a mel-
anoma deposit. However, several studies have demon-
strated that surgical transection of a primary melanoma at
initial biopsy does not affect patient survival, regardless of
biopsy technique employed [30-32].
Our study is the first to demonstrate that changes in
ctDNA may be predictive of the anti-tumor activity of im-
mune checkpoint blocking drugs. Further study involving
larger numbers of patients is needed to assess the utility of
ctDNA levels in detecting fluctuations in tumor burden
prior to clinically or radiographically measureable changes
in patients receiving these agents.
Additional file
Additional file 1: Table S1. Methods used for mutational analysis of
tumor tissue for the 5 patients in our study in whom a genetic mutation
was detected.
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